Biotech "Tweets of the Week"
Biotech Revival
(April 4-8, 2016)
Headlines - $AGN $ALDR $ICPT $PFE $RLYP
In the News - $INCY $IONS $PETX $PGNX $PIRS $SRNE $SRPT $TTPH $VRX
$XBI $IBB $LABU
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
Treasury Dept squashes Pfizer-Allergan inversion $PFE $AGN
$AGN down 15% as Treasury tries to block tax inversions. https://t.co/JhZlNEFETP
— Max Nisen (@MaxNisen) April 4, 2016
$PFE and $AGN on Treasury's new anti-inversion rules: Reviewing and until done, "we won't speculate on any potential impact."
— Jonathan Rockoff (@jonathanrockoff) April 4, 2016
Evercore ISI's Raffat: Usable $AGN equity for purposes of inversion down to Warner Chilcott, less than 20%. $PFE $AGN is dead.
— Jon Gardner (@ByJonGardner) April 5, 2016
BREAKING: Pres. Obama to make statement on tax inversions from the White House at 12:15p ET
— CNBC Now (@CNBCnow) April 5, 2016
*PFIZER, ALLERGAN TO TERMINATE MERGER TOMORROW MORNING: CNBC- per Bbg
— Vikram (@biotechinvstr) April 6, 2016
$PFE Announces Termination of Proposed Combination with $AGN https://t.co/ed0lulU1Zt
— Bio Stocks™ (@BioStocks) April 6, 2016
"Everything is on the table" when $AGN closes the $TEVA generics deal CEO @brentlsaunders says
— Sasha Damouni Ellis (@SashaDamouni) April 6, 2016
twitter absurdity at it's best this morning with hilarious $AGN M&A spec
— zach (@zbiotech) April 6, 2016
Fortunately4 $AGN, they own what is perhaps the best asset in the drug/biotech industry: Botox.
— Roy Friedman (@DewDiligence) April 6, 2016
$PFE $AGN falling part is the best thing to happen to spec. pharma in the past six months.
— Jason Napodano, CFA (@JNapodano) April 6, 2016
"We broke up today."
— Joe (@Drchik23) April 7, 2016
"Are you ok?"
"Oh totally. Already found someone new."$agn #heptares
Sosei bought Heptares for $180. Now $AGN gives it $125m up front for just a phase I Heptares CNS programme
— Jacob Plieth (@JacobPlieth) April 7, 2016
$AGN 244.74
— Tom Wrigley (@WrigleyTom) April 7, 2016
resumed at Overweight, PT $300
-Morgan Stanley pic.twitter.com/aKfAsVgqPW
Ian Read's op-ed: Obama is unfair to me, the rules are unfair, U.S. taxes are unfair; and it's not easy being a multinational megacorp. $PFE
— John Carroll (@JohnCFierce) April 7, 2016
Financing market thaws for Alder $ALDR
$ALDR 100m offering
— zach (@zbiotech) April 6, 2016
@VM1409 @zbiotech they have ~400M and "cash until the end of 2017" per them. Don't understand raising 100M here $ALDR
— NSharma (@Sharma1981N) April 6, 2016
@WilliamGerber1 Yes. With another 800k shares more, possibly. ~10% discount to today's closing price.
— Joe (@Drchik23) April 7, 2016
@srqstockpicker Being able to raise money and having cash is definitely a signal of strength in this market.
— Brad Loncar (@bradloncar) April 7, 2016
$ALDR priced at $23.25....up ~15%
— zach (@zbiotech) April 7, 2016
Intercept aces FDA panel for first liver disease indication $ICPT
$ICPT #FDA briefing docs up https://t.co/QnRqUgyf9P #pharma #biotech
— Donna Young (@ScripDonnaDC) April 5, 2016
$ICPT PT raised to $266-$280 from $162-$180 at Wells
— Bio Stocks™ (@BioStocks) April 5, 2016
Took 3/4 of my $icpt off from Monday, great move more than what I expected
— Syed Shah MPH (@shahofNY) April 6, 2016
$ICPT #adcomm: FDA slide showing that its proposed cutoffs demonstrate wider separation on KM curve pic.twitter.com/tMeL3djZf2
— SAC Tracker (@FDAadcomm) April 7, 2016
$ICPT — The FDA safety presentation on OCA was more concerning about NASH indication than PBC. Keep that in mind.
— Adam Feuerstein (@adamfeuerstein) April 7, 2016
$ICPT adcomm VOTE: Is there substantial evidence to support AA of OCA for the proposed indication, based on its effect on ALP?
— SAC Tracker (@FDAadcomm) April 7, 2016
17-Y
0-N
Rumors, Shorts, and Relypsa $RLYP
$RLYP Now hearing they are reviewing offers from potential suitors.
— Open Outcrier (@OpenOutcrier) April 7, 2016
@princetongb Even a greater impact (+) could come from rival drug ZS9 receiving a black box label or delay on May26, its PDUFA day.Go $RLYP!
— Helen Ong (@Lin_ling_88) April 7, 2016
41% of $RLYP float is short
— zach (@zbiotech) April 7, 2016
Cantor says $RLYP deal makes sense.
— HumbleBioTrader (@HumbleBioTrader) April 7, 2016
Source: TOS
$RLYP Would this be a good enough "non-dilutive financing" for everyone?
— NSharma (@Sharma1981N) April 7, 2016
As seen on the stream
$GILD $ICPT $CLVS $CHMA $HRTX $PGNX $SRPT $COLL $FLML $SUPN Biotech Stocks Facing FDA Decision In April https://t.co/DibXFuwSsN
— BioBreakout (@BioBreakout) April 3, 2016
Nimbus Delivers Its Apollo Mission: A $1.2B Gilead Partnership. https://t.co/XY9R7G4RGK
— Bruce Booth (@LifeSciVC) April 4, 2016
@vlad33301 Sold anther third @ 6.81. Gain of 83% on that batch.
— vlad33301 (@vlad33301) April 4, 2016
@SheffStation $PIRS "let your winners run"
— judith (@judith00639098) April 4, 2016
$VRX *VALEANT SAID TO TERMINATE ADDYI SALES FORCE IN REORGANIZATION
— zach (@zbiotech) April 4, 2016
$LABD..$48.50 here. That was easy money this a.m. Will be interesting to see if it moves much higher this a.m.
— Sheff (@SheffStation) April 5, 2016
Took gains in few bios here from buying Feb lows. Which sounds nice but actually just gets me back to slightly under par for year ¯\_(ツ)_/¯
— Adam Singer (@AdamSinger) April 5, 2016
$PGNX FDA delayed - they wanna see $VRX 10-K first or something
— Red Acre Investments (@redacre) April 5, 2016
That we have 2 biosimilars now approved in US & that IPO market is back from the dead is more intriguing to me than all this $agn talk.
— Joe (@Drchik23) April 6, 2016
Drug developers led the FTSE today given renewed M&A excitement post PFE-AGN. Hope that’s the case for us today too. https://t.co/TwjkN3cY0j
— Brad Loncar (@bradloncar) April 6, 2016
$SRNE entered agreements in 4 separate, private placement deals, of up to $150M in additional funding. Ouch
— dough (@tgtxdough) April 6, 2016
$XBI $IBB Id keep a cautious eye out for financing..companies will seize the chance to raise money while the market is super hot.
— roy vimer (@roiev123) April 6, 2016
Big $CPXX has my fundamental brain in a brawl with my technical brain.
— Olddogwithnewtrix (@olddoggnewtrix) April 6, 2016
GO GO GO GO ! $SRPT Over 21,23 its a breakout ! pic.twitter.com/hJI2i98gfg
— Bursatil Biotech (@BursatilBiotech) April 6, 2016
I'm no chartist, but this market does not look trustworthy at all. Building up my shorts as we get closer to $IBB $300
— Julia Skripka-Serry (@JuliaSkripkaSer) April 6, 2016
Biofrenzy™
— StockCats (@StockCats) April 6, 2016
@Sport234a poooor inversion CEOs. now they actually have to grow revenues the old fashioned way.
— Colfax (@ColfaxCapital) April 6, 2016
$INCY just increased the price of Jakafi by 6%, more aggressive vs 4% price increase taken in 9/2015 and a 5% increase in 3/2015. [Cowen]
— Andy Biotech (@AndyBiotech) April 6, 2016
$SRPT Shooting up $21.90 ... is it a short covering, anyone feels uncomfortable at this point ahead of the AdCom?
— Joe (@GantosJ) April 6, 2016
$IBB bio buyer du jour?:"Hey $PFE could not buy that $AGN cash cow, must means they going to buy some no revenue bios, for sure!" whaaa?...
— Jean Fonteneau (@JFinDallas) April 6, 2016
Even $CLVS participated today
— PropThink (@PropThinker) April 6, 2016
Today's market summary: $AGN will buy every SMID biotech known to $MNKD (except for $MNKD)
— DCam (@dcamtrades) April 6, 2016
— Patrick (@bostonbiomed) April 6, 2016
$MDT -- FDA approves first leadless pacemaker to treat heart rhythm disordershttps://t.co/t70N5MVQsL
— Andy Biotech (@AndyBiotech) April 7, 2016
Micra System pic.twitter.com/Umo8TjDdRO
83% of all tickers in $IBB $XBI $SBIO $BBC $BBP are above their 50ma. I'd expect many of these to retest their 50ma after this biotech rally
— BioBounce.com (@BioBounce) April 7, 2016
$IBB closed the gap to $286 in a single day. Even my perfect world didn't see that one coming. So what now, biotech?
— WhiteCoatMafia (@WhiteCoatMafia) April 7, 2016
That was the quickest bought up dip of all time.
— Festo (@Festo50) April 7, 2016
Ah come on...don't give up so easy.
— Festo (@Festo50) April 7, 2016
$ions clinical hold should not last long: Piper Jaffray Looks like delay to trial start to check more boxes on monitoring.Reiterates $80 pt
— Douglas Allan (@Dougallan1) April 7, 2016
$IONS @Sport234a FDA placed clinical hold due to questions "stemming from ongoing NEURO-TTR study". So will that study be put on hold next?
— Andy Biotech (@AndyBiotech) April 7, 2016
@tsullivan70 speculative now, huge potential with minimal downside $ttph
— Pharm. D (@Pharmdca) April 7, 2016
Beautiful photos capture a brighter future in Sierra Leone thanks to the power of vaccines. https://t.co/wNDyAkC5ya pic.twitter.com/Re0ki9tjMm
— Sue Desmond-Hellmann (@SueDHellmann) April 7, 2016